MARKET

OPK

OPK

Opko Health
NASDAQ
1.890
+0.020
+1.07%
Closed 19:49 09/30 EDT
OPEN
1.860
PREV CLOSE
1.870
HIGH
1.950
LOW
1.860
VOLUME
2.06M
TURNOVER
--
52 WEEK HIGH
5.25
52 WEEK LOW
1.780
MARKET CAP
1.46B
P/E (TTM)
-6.3938
1D
5D
1M
3M
1Y
5Y
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Zacks · 6d ago
Eton Pharmaceuticals, GeoVax Labs And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Nasdaq Composite dropped by around 200 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 09/26 12:48
Investors five-year losses grow to 65% as the stock sheds US$139m this past week
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...
Simply Wall St. · 09/05 16:28
3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.
Zacks · 08/23 14:30
Key Opko Health executive retires
Opko Health (Nasdaq: OPK) announced Dr. Jon R. Cohen has retired as executive chairman and CEO of its BioReference Laboratories subsidiary. Cohen also retired from his role as senior VP and director of Miami-based Opko, although he will remain an employed...
American City Business Journals · 08/17 17:51
The OPKO Health, Inc. (NASDAQ:OPK) Analysts Have Been Trimming Their Sales Forecasts
The analysts covering OPKO Health, Inc. ( NASDAQ:OPK ) delivered a dose of negativity to shareholders today, by making...
Simply Wall St. · 08/09 15:56
OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.
Zacks · 08/09 13:14
--Piper Sandler Adjusts OPKO Health's Price Target to $4 From $5, Reiterates Overweight Rating
--Piper Sandler Adjusts OPKO Health's Price Target to $4 From $5, Reiterates Overweight Rating
MT Newswires · 08/05 06:58
More
About OPK
OPKO Health, Inc. is a healthcare company. The Company’s segments include Diagnostics and Pharmaceutical. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP and hGH-CTP. It also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.

Webull offers kinds of Opko Health Inc. stock information, including NASDAQ:OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.